Company intelligence / Profile preview

CannBioRx Pharmaceuticals

Toronto, Ontario, Canada

Ownership: Private
Development stage: Other

Overview

CannBioRx Life Sciences is a drug development company focused on inflammatory diseases, with a diversified pipeline spanning pre-clinical to late clinical-stage programs. Its scientific strategy emphasizes both biologic and synthetic small molecule approaches, including man-made cannabinoids, and leverages expertise in immunology and neurology from its leadership team. The company was in talks to be acquired by KBL Merger Corp. IV, which would amalgamate CannBioRx’s programs with two other synergistic biotech initiatives, but the transaction’s completion is not confirmed in the available data[7].

Therapeutic areas: ImmunologyEndocrinologyRheumatologyNeurologyOther
Modalities: Small moleculeBiologicOrally available therapySynthetic cannabinoid
Industry: Biotech

Beyond the preview

Go deeper on CannBioRx Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CannBioRx Pharmaceuticals.

Explore the full profile